Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

436.70INR
5:59am EDT
Price Change (% chg)

Rs1.70 (+0.39%)
Prev Close
Rs435.00
Open
Rs433.00
Day's High
Rs444.80
Day's Low
Rs430.50
Volume
126,940
Avg. Vol
226,793
52-wk High
Rs460.45
52-wk Low
Rs366.70

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin... (more)

Overall

Beta: 0.50
Market Cap (Mil.): Rs350,113.81
Shares Outstanding (Mil.): 802.92
Dividend: 2.00
Yield (%): 0.46

Financials

  CIPL.BO Industry Sector
P/E (TTM): 25.23 35.07 35.49
EPS (TTM): 17.29 -- --
ROI: -- 18.94 18.21
ROE: -- 19.73 19.11
Search Stocks

UPDATE 1-S.African govt awards $33 mln respiratory contract to Cipla

CAPE TOWN, June 26 - South Africa has awarded Cipla Medpro a 345 million rand ($32.6 million) share in the national respiratory tender as Africa's most advanced economy seeks to cut high asthma mortality rates, the company said on Thursday.

26 Jun 2014

S.African govt awards $33 mln respiratory contract to Cipla

CAPE TOWN, June 26 - South Africa has awarded Cipla Medpro a 345 million rand ($32.6 million) share in the national respiratory tender as Africa's most advanced economy seeks to cut high asthma mortality rates, the company said on Thursday.

26 Jun 2014

UPDATE 1-Indian shares fall over 1 pct on Iraq conflict; Fed on watch

* BSE index falls 1.1 pct; NSE index down 0.96 pct * Cipla touches 8-1/2 month high on stake-sale talk * Reliance slumps post annual shareholder meeting (Adds more stocks, and updates price action) By Abhishek Vishnoi MUMBAI, June 18 - Indian shares slipped more than 1 percent on Wednesday, falling for three out of four sessions as blue-chips including oil refiners slumped on concerns about the impact of higher oil prices on inflation and the government's finances.

18 Jun 2014

India's Cipla Q4 net profit down 3 pct on higher costs

MUMBAI, May 29 - Indian drugmaker Cipla Ltd on Thursday reported a 3 percent drop in fourth-quarter net profit, slightly below analysts' estimates due to higher raw material and employee expenses.

29 May 2014

INDIA PRESS-Cipla may put patent for new HIV drug in open access pool-Mint

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Abhiram Nandakumar in Bangalore)

10 Mar 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: BuySellSignals Research
$5.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: BuySellSignals Research
$5.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks